Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ALLO Allogene Therapeutics Inc

2,73

-0,13 (-4,55%)

10 Mai 2024 - Geschlossen

Verzögert um 15 Minuten

Form 3 - Initial statement of beneficial ownership of securities

Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Allogene Therapeutics Charts.

Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Allogene Therapeutics Charts.

News Allogene Therapeutics Inc

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Montag 6 Mai 2024 (5 Tage vor) • GlobeNewswire Inc.

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Freitag 26 April 2024 (2 Wochen vor) • GlobeNewswire Inc.

Allogene Therapeutics Announces Q2 Investor Conference Participation
Dienstag 9 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Donnerstag 14 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Dienstag 12 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Dienstag 5 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Mittwoch 28 Februar 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Freitag 16 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Freitag 16 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 31 Januar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 24 Januar 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Montag 22 Januar 2024 (4 Monate vor) • Edgar (US Regulatory)

Weitere Allogene Therapeutics Inc News-Artikel

JP Morgan Chase

Euro vs Sterling

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen